Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Accenture
Argus Health
Deloitte
Colorcon
Julphar
McKinsey
Cerilliant
Baxter

Generated: April 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,143,326

« Back to Dashboard

Summary for Patent: 6,143,326
Title: Oral pharmaceutical preparation containing ibandronat
Abstract:The invention is directed to well-tolerated pharmaceutical compositions for oral application, containing ibandronate or a physiologically tolerable salt thereof as active substance, the administration form consisting of an active substance-containing inner portion enclosed in such fashion by a coat free of active substance that rapid release of the active substance takes place.
Inventor(s): Mockel; Jorn (Heidelberg, DE), Gabel; Rolf-Dieter (Schwetzingen, DE), Woog; Heinrich (Laudenbach, DE)
Assignee: Roche Diagnostics GmbH (Mannheim, DE)
Application Number:09/147,149
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Dosage form;

Drugs Protected by US Patent 6,143,326

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,143,326

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany196 15 812Apr 20, 1996
PCT Information
PCT FiledApril 21, 1997PCT Application Number:PCT/EP97/01940
PCT Publication Date:October 30, 1997PCT Publication Number: WO97/39755

International Patents Family Members for US Patent 6,143,326

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Slovenia 0936913 ➤ Try a Free Trial
Russian Federation 2193881 ➤ Try a Free Trial
Portugal 936913 ➤ Try a Free Trial
Poland 191910 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
AstraZeneca
Chubb
Accenture
McKinsey
Deloitte
Cantor Fitzgerald
Daiichi Sankyo
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.